Anastrozole

Anastrozole

SCHEMBL3172308

CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1.Cl

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CYP19A1

The experimentally established mechanism targets of Anastrozole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CYP19A1 known ✓ P11511 19/20 0.97
UGT1A4 P22310 1/20 0.97
PDE4D Q08499 1/20 0.97
ESR1 P03372 1/20 0.56
STS P08842 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Anastrozole SCHEMBL27927481 0.99 CYP19A1 (1.00) CYP19A1UGT1A4PDE4DESR1STS
Anastrozole SCHEMBL9726 0.99 CYP19A1 (1.00) CYP19A1UGT1A4PDE4DESR1STS
Anastrozole SCHEMBL177942 0.99 CYP19A1 (1.00) CYP19A1UGT1A4PDE4DESR1STS
Anastrozole SCHEMBL5917785 0.97 CYP19A1 (0.97) CYP19A1UGT1A4PDE4DESR1STS
Anastrozole SCHEMBL28771766 0.97 CYP19A1 (0.97) CYP19A1UGT1A4PDE4DESR1STS
SCHEMBL10324455 0.94 CYP19A1 (0.92) CYP19A1UGT1A4PDE4DESR1STS
Anastrozole SCHEMBL13323739 0.93 CYP19A1 (0.90) CYP19A1UGT1A4PDE4DESR1STS
SCHEMBL8059026 0.92 CYP19A1 (0.87) CYP19A1UGT1A4PDE4DESR1STS
Hydrochloric Acid SCHEMBL8058748 0.91 CYP19A1 (0.81) CYP19A1UGT1A4PDE4DESR1STS
Anastrozole SCHEMBL354747 0.91 CYP19A1 (0.85) CYP19A1UGT1A4PDE4DESR1STS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060035950-A1 Novel processes for preparing substantially pure anastrozole CHEMAGIS LTD. (IL) 2006-02-16 US claimed
EP-2024343-B1 PROCESS FOR PURIFICATION OF ANASTROZOLE SYNTHON BV (NL) 2015-09-09 EP disclosed
CN-101568526-B Process for purification of anastrozole SYNTHON BV 2013-03-06 CN disclosed
US-7655806-B2 Process for purification of anastrozole SYNTHON BV (NL) 2010-02-02 US disclosed
CN-101568526-A Process for purification of anastrozole SYNTHON BV (NL) 2009-10-28 CN disclosed
EP-2024343-A2 PROCESS FOR PURIFICATION OF ANASTROZOLE Synthon B.V. (NL) 2009-02-18 EP disclosed
WO-2009010991-A2 PURIFICATION PROCESS TO PREPARE HIGHLY PURE ANASTROZOLE IND-SWIFT LABORATORIES LIMITED (IN) 2009-01-22 WO disclosed
US-20070281982-A1 PROCESS FOR PURIFICATION OF ANASTROZOLE SYNTHON BV (NL) 2007-12-06 US disclosed
WO-2007134846-A2 PROCESS FOR PURIFICATION OF ANASTROZOLE SYNTHON B.V. (NL) 2007-11-29 WO disclosed
US-20060035950-A1 Novel processes for preparing substantially pure anastrozole CHEMAGIS LTD. (IL) 2006-02-16 US disclosed
WO-2005105762-A1 IMPROVED PROCESS FOR THE PREPARATION OF HIGH PURITY ANASTROZOLE NATCO PHARMA LIMITED (IN) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281982-A1 PROCESS FOR PURIFICATION OF ANASTROZOLE CYP19A1, HSD17B11, ADH1A CYP19A1 1/4885UGT1A4 254/4885PDE4D 1560/4885
US-20060035950-A1 Novel processes for preparing substantially pure anastrozole CYP19A1, CYP11A1, CYP4B1 CYP19A1 1/4885UGT1A4 1143/4885PDE4D 950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.